alexa Engineered T Cells: Next-generation Cancer Immunotherapy
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference and Exhibition on Clinical & Cellular Immunology
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Rahul Purwar
ScientificTracks Abstracts: J Clin Cell Immunol
DOI: 10.4172/2155-9899.S1.017
Abstract
Cancer immunotherapy is an emerging and a transformative approach for the treatment of cancer patients. Although localized tumors especially breast cancer and skin cancer (melanoma) can be cured by surgical treatment, once cancer metastasizes, survival is limited. Immunotherapy is one of the best treatment options for patients with metastatic cancer, however benefits of available immunotherapy are limited because of following: 1) Only a minor subgroup of patients show objective response to particular immunotherapy. 2) Current immunotherapy focuses on life-extension by only few months. Therefore, there is an urgent need of exploring novel strategies for the development of robust cancer therapy. Cancer of each patient is unique and personalized approach would be an ideal for successful cancer treatment: Engineering immune-system that target antigen specific to each patient. Adoptive T cell therapy with engineered autologous T cells is unique and personalized for each patient and has potential for the eradication of cancer. Treatments with engineered CAR-T cells have generated some remarkable responses in patients with advanced cancer (acute lymphocytic leukemia patients and chronic lymphocytic leukemia (CLL) patients). Recently, we demonstrated that adoptive transfer of tumor-specific Th9 cells strongly inhibited melanoma tumor growth, and increased the duration of survival. Th9 cells inhibited melanoma growth in both normal and lymphopenic hosts, through both IL-9 dependent and independent pathways. More importantly, Th9 cells were superior in controlling tumor growth compared to other T cells. In conclusion, adoptive T cell therapy of cancer using engineered T cells comes of age and may provide effective cancer cure.
Biography
Rahul Purwar has completed his PhD from Hannover Medical School, Hannover, Germany and Postdoctoral studies from Harvard Medical School, Boston, USA. He has worked for an Oncology company, ImmunoGen Inc., Waltham, USA, before returning to India to join IIT-Bombay as an Assistant Professor. He has published several papers in reputed journals and has received many awards.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords